

SUPPLEMENTAL TABLE S1. Main demographic and clinical characteristics of the study sample stratified by BMI data availability

	<b>BMI data available N=406</b>	<b>BMI data missing N=90</b>	<b>p-value</b>
<b>Age in years, mean (SD)</b>	64.6 (12.6)	64.6 (16.2)	0.986
<b>Female, n (%)</b>	341 (84.0)	72 (80.0)	0.360
<b>Hispanic ethnicity, n (%)</b>	12 (3.0)	3 (3.3)	0.857
<b>Race, n (%)</b>			
White	373 (91.9)	83 (92.2)	0.095
Black or African-American	10 (2.5)	1 (1.11)	0.155
Asian	20 (5.0)	5 (5.6)	0.230
<b>NTM presence<sup>a</sup>, n (%)</b>	220 (54.2)	51 (56.7)	0.669
<b><i>Pseudomonas Aeruginosa</i><sup>b</sup>, n (%)</b>	105 (35.5)	19 (35.2)	0.968
<b>Smoking status, n (%)</b>			0.023
Current smoker	2 (0.5)	1 (1.2)	
Former smoker	156 (41.1)	22 (26.5)	
Non-smoker	222 (58.4)	60 (72.3)	
<b>Ever diagnosed with AATD, n (%)</b>	10 (2.6)	0 (0.00)	0.391
<b>Ever diagnosed with primary immunodeficiency, n (%)</b>	20 (5.3)	4 (4.9)	0.350
<b>Ever diagnosed with Kartagener's syndrome or PCD, n (%)</b>	9 (2.4)	5 (6.0)	0.217

<b>Ever diagnosed with a rheumatologic disease<sup>c</sup>, n (%)</b>	28 (7.5)	2 (2.5)	0.270
<b>Any pulmonary exacerbations in the past 2 years, n (%)</b>	229 (63.4)	47 (58.8)	0.434
<b>Any hospitalization for pulmonary illness or exacerbation in the past 2 years, n (%)</b>	68 (18.8)	17 (21.3)	0.621
<b>Pre-Bronchodilator: FEV1 (% predicted), mean (SD)</b>	72.3 (21.1)	70.1 (20.9)	0.408
<b>Pre-Bronchodilator: FVC (% predicted), mean (SD)</b>	80.6 (18.0)	81.8 (21.3)	0.650
<b>FEV1 (L)/FVC(L), mean (SD)</b>	0.7 (0.1)	0.7 (0.1)	0.459
<b>Lung resection (pneumonectomy and/or lobectomy), n (%) (data available n=71)</b>	36 (63.2)	8 (57.1)	0.680

BMI – body mass index; SD- standard deviation; NTM – non-tuberculous mycobacteria; AATD = Alpha-1 Antitrypsin Deficiency; PCD = Primary Ciliary Dyskinesia; FEV1 – Forced expiratory volume in 1 second; FVC – forced vital capacity;

<sup>a</sup> Defined as those with either a reported history of pulmonary NTM disease and/or those with one or more NTM isolates in respiratory specimen cultures at baseline

<sup>b</sup> Defined as one or more positive cultures at baseline

<sup>c</sup> Rheumatologic disease including Rheumatoid Arthritis (RA), Sjogren’s syndrome